Modality
Cell Therapy
MOA
TYK2i
Target
FLT3
Pathway
PD-1/PD-L1
GBMNASH
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
~Jun 2023
→ ~Sep 2024
Phase 2
Dec 2024
→ Mar 2028
Phase 2Current
NCT06937706
628 pts·GBM
2024-12→2028-03·Not yet recruiting
NCT07362671
519 pts·NASH
2025-12→2027-03·Terminated
1,147 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-0911mo awayPh2 Data· NASH
2028-03-031.9y awayPh2 Data· GBM
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2027-03-09 · 11mo away
NASH
Ph2 Data
2028-03-03 · 1.9y away
GBM
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06937706 | Phase 2 | GBM | Not yet recr... | 628 | EDSS |
| NCT07362671 | Phase 2 | NASH | Terminated | 519 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |